tbuckley/cabot-search huggingface dataset:
Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories
Authors: Connor Bargar, Chiara Maria Giulia De Luca, Grazia Devigili, Antonio Emanuele Elia, Roberto Cilia, Sara Maria Portaleone, Wen Wang, Irene Tramacere, Edoardo Bistaffa, Federico Angelo Cazzaniga, Giovanni Felisati, Giuseppe Legname, Alessio Di Fonzo, Rong Xu, Steven Alexander Gunzler, Giorgio Giaccone, Roberto Eleopra, Shu Guang Chen, Fabio Moda
Journal: Molecular Neurodegeneration (2021)

Detection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson's disease (PD). We recently showed that αSynD can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes.OM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data.The αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83-1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability.Our study provides evidence that OM-αSynD may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials.
Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD
Authors: Liang-Jie Tang, Hong-Lei Ma, Mohammed Eslam, Grace Lai-Hung Wong, Pei-Wu Zhu, Sui-Dan Chen, Diana Julie Leeming, Morten Karsdal, Gang Li, Ou-Yang Huang, Howard Ho-Wai Leung, Yu-Jie Zhou, Qian Feng, Pei Jiang, Li-Mei Gao, Christopher D. Byrne, Giovanni Targher, Jacob George, Vincent Wai-Sun Wong, Ming-Hua Zheng
Journal: Metabolism (2021)
Au@Ag Nanorods‐PDMS Wearable Mouthguard as a Visualized Detection Platform for Screening Dental Caries and Periodontal Diseases
Authors: Dongxu Ma, Baiqi Chen, Yuanfang Li, Xueyuan Pang, Quanying Fu, Zihan Xiao, Zhonghong Shi, Xiaolei Li, Chongdai Luo, Zhang‐kai Zhou, Yin Chen, Jianhua Zhou
Journal: Advanced Healthcare Materials (2021)

The development of easy-to-use, low-cost, and visualized detection platforms for screening human dental caries and periodontal diseases is in urgent demand. In this work, a Au@Ag nanorods-poly(dimethylsiloxane) (Au@Ag NRs-PDMS) wearable mouthguard, which can visualize the tooth lesion sites through the color change of it at the corresponding locations, is presented. The Au@Ag NRs-PDMS composite exhibits a distinct color response to hydrogen sulfide (H2 S) gas generated by bacterial decay at the lesion sites. Moreover, the Au@Ag NRs-PDMS mouthguard is demonstrated to own desired mechanical properties, excellent chemical stability, as well as good biocompatibility, and can accurately locate the lesion sites in human oral cavity. These findings suggest that the mouthguard has the potential to be utilized on a large scale to help people self-monitor their oral health in daily life, and treat oral diseases locally.
Shall the Calories Be Forgotten?
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Across-the-papilla side-by-side deployment of three braided stents for malignant hilar biliary obstruction
Authors: Saori Ueno, Takeshi Ogura, Jyunichi Kawai, Masahiro Yamamura, Kazuhide Higuchi
Journal: Endoscopy (2021)

Malignant hepatic hilar obstruction is treated by biliary stenting under the guidance of endoscopic retrograde cholangiopancreatography. In inoperable cases, uncovered self-expandable metal stents (SEMSs) may be deployed for palliative drainage [1] [2] [3] [4]. Multiple SEMS deployment using the stent-in-stent (SIS) technique is challenging, especially in nonexpert hands. The side-by-side (SBS) technique is considered easier than the SIS technique, but simultaneous deployment of three SEMSs using the SBS technique is also challenging. Recently, a novel 6-mm fully covered SEMS (FCSEMS) with a 6-Fr stent delivery system (EGIS braided 6; S&G Biotech Inc., Yongin-si, South Korea) has become available in Japan ([Fig. 1]). Because of the fine gauge of the stent delivery system, second and third stent insertions beside the first stent deployment may be feasible. We describe technical tips for SBS deployment of three stents in one case.
β3‐Adrenoceptor, a novel player in the round‐trip from neonatal diseases to cancer: Suggestive clues from embryo
Authors: Luca Filippi, Alessandro Pini, Maurizio Cammalleri, Paola Bagnoli, Massimo Dal Monte
Journal: Medicinal Research Reviews (2021)

Abstract The role of the β‐adrenoceptors (β‐ARs) in hypoxia‐driven diseases has gained visibility after the demonstration that propranolol promotes the regression of infantile hemangiomas and ameliorates the signs of retinopathy of prematurity (ROP). Besides the role of β2‐ARs, preclinical studies in ROP have also revealed that β3‐ARs are upregulated by hypoxia and that they are possibly involved in retinal angiogenesis. In a sort of figurative round trip, peculiarities typical of ROP, where hypoxia drives retinal neovascularization, have been then translated to cancer, a disease equally characterized by hypoxia‐driven angiogenesis. In this step, investigating the role of β3‐ARs has taken advantage of the assumption that cancer growth uses a set of strategies in common with embryo development. The possibility that hypoxic induction of β3‐ARs may represent one of the mechanisms through which primarily embryo (and then cancer, as an astute imitator) adapts to grow in an otherwise hostile environment, has grown evidence. In both cancer and embryo, β3‐ARs exert similar functions by exploiting a metabolic shift known as the Warburg effect, by acquiring resistance against xenobiotics, and by inducing a local immune tolerance. An additional potential role of β3‐AR as a marker of stemness has been suggested by the finding that its antagonism induces cancer cell differentiation evoking that β3‐ARs may help cancer to grow in a nonhospital environment, a strategy also exploited by embryos. From cancer, the round trip goes back to neonatal diseases for which new possible interpretative keys and potential pharmacological perspectives have been suggested.
Comparison of a Hemostatic Powder and Standard Treatment in the Control of Active Bleeding From Upper Nonvariceal Lesions
Authors: James Y.W. Lau, Rapat Pittayanon, Andrew Kwek, Raymond S. Tang, Heyson Chan, Rungsun Rerknimitr, June Lee, Tiing Leong Ang, Bing-Yee Suen, Yuan-yuan Yu, Francis K.L. Chan, Joseph J.Y. Sung
Journal: Annals of Internal Medicine (2021)

Background: The effectiveness of the hemostatic powder TC-325 as a single endoscopic treatment for acute nonvariceal upper gastrointestinal bleeding is uncertain. Objective: To compare TC-325 with standard endoscopic hemostatic treatments in the control of active bleeding from nonvariceal upper gastrointestinal causes. Design: One-sided, noninferiority, randomized, controlled trial. (ClinicalTrials.gov: NCT02534571) Setting: University teaching hospitals in the Asia-Pacific region. Patients: 224 adult patients with acute bleeding from a nonvariceal cause on upper gastrointestinal endoscopy. Intervention: TC-325 (n = 111) or standard hemostatic treatment (n = 113). Measurements: The primary outcome was control of bleeding within 30 days. Other outcomes included failure to control bleeding during index endoscopy, recurrent bleeding after initial hemostasis, further interventions, blood transfusion, hospitalization, and death. Results: 224 patients were enrolled (136 with gastroduodenal ulcers [60.7%], 33 with tumors [14.7%], and 55 with other causes of bleeding [24.6%]). Bleeding was controlled within 30 days in 100 of 111 patients (90.1%) in the TC-325 group and 92 of 113 (81.4%) in the standard treatment group (risk difference, 8.7 percentage points [1-sided 95% CI, 0.95 percentage point]). There were fewer failures of hemostasis during index endoscopy with TC-325 (3 [2.7%] vs. 11 [9.7%]; odds ratio, 0.26 [CI, 0.07 to 0.95]). Recurrent bleeding within 30 days did not differ between groups (9 [8.1%] vs. 10 [8.8%]). The need for further interventions also did not differ between groups (further endoscopic treatment: 8 [7.2%] vs. 10 [8.8%]; angiography: 2 [1.8%] vs. 4 [3.5%]; surgery: 1 [0.9%] vs. 0). There were 14 deaths in each group (12.6% vs. 12.4%). Limitation: Clinicians were not blinded to treatment. Conclusion: TC-325 is not inferior to standard treatment in the endoscopic control of bleeding from nonvariceal upper gastrointestinal causes. Primary Funding Source: General Research Fund to the University Grants Committee, Hong Kong SAR Government.
Aligned human induced pluripotent stem cell-derived cardiac tissue improves contractile properties through promoting unidirectional and synchronous cardiomyocyte contraction
Authors: Takuma Takada, Daisuke Sasaki, Katsuhisa Matsuura, Koichiro Miura, Satoru Sakamoto, Hiroshi Goto, Takashi Ohya, Tatsuro Iida, Jun Homma, Tatsuya Shimizu, Nobuhisa Hagiwara
Journal: Biomaterials (2021)
JAMA Internal Medicine
Authors: Thomas Easley, Brian Shields, Karen Adams-Taylor, Paul Gee, Monica Smith, Jeff Ery, J Bonistalli, Kathy Russell, Mirna Monal, Stacey Mchugh, Tim Melroy, Marketing Thornbury, Tricia Castellano, Anna Frazier, Megan Thue, Sade Deramus- Townsend, Thalia Moss, Tony Ralenkotter, Marsha Fogler, Rachel Sisholtz, Saskia Bolore, Gretchen Linder, Brian Mccartney, Christine Hearne, Natasha Staff, Henry Aguillon, David Baum, Ron Marketing, Rick Bell, Elizabeth Solaro, Sara Zimmerman, Geoff Rey, Lindsay Dawson, Ellen Gibson, Craig Mccaff Rey, Michael Mcgraw, Daniel Pickhardt, Romando Rossini, Sarah Subramanian, Stacy Tucker, Walsh Business, Analyst Sirisha, Alluri Staff, Millette Jackson-Bates, Tom Miller, Jacob Mishkin, Morgan Business, Karl Elvin, Nancy Essex, Jaye Mize, Sean O'donnell, Sue Managers, David Antos, Anthony Bautista, Chris Borden, Debbie Camp, Jennifer Carney, Lydia Cruz, Scott Curl, Diane Darnell, Nanette Diaz, Jordynn Farrar, Allison Hughes, Colleen Kelly, John Lash, Chris Meyer, Annemarie Neff, J Neff, Sean Ohlson, Phil O'leary, Bill Pedone, Susan Price, Jaynam Shah, Erin Spencer, Denise Steinhauser, Joe Advertising, Production Services, Ahmed Avendano, Kim Boler, Rhonda Brown, Fin Carter, Michael Deegan, Daniel Degroot, Euwanaha Joiner-Smith, Joshua Lane, Cindy Rendlen, Ellen Yoshihara, Annissa Zak, Circulation Services, Julie Burton, Ronna Hewitt, Mary Sieck, Geneine Someren, Jamaal Vargas, Content Systems, Mike Bujewski, Nathan Mitre, Digital Production, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Maleeka Holden, Teri Hutchison, Dan Knowles, Joshua Lampinen, Natalie Marsh, Patricia Panek, Marla Seidell, La Son Diggs-Sledge, Julian Graphics, Joe Amft, Jonathan Chala, James Collver, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Maria Giannini, Sasha Grossman, Kate Lander, Judith Literskis, Teresa Omiotek, Michael Ryder, James Madara, Fellows Mithi, Del Rosario, Vinay Guduguntla, Anand Habib, Audrey Han, Natalie Richmond, Eric Ward, Zachary Goldberger, Nora Goldschlager, San Francisco, Elsayed Soliman, Carolina Cme, Jeff Rey Tabas, Fiona Clement, Rita Redberg, Deborah Grady, Michael Incze, Salt City, Tanner Caverly, Ann Arbor, Brandon Combs, Sanket Dhruva, New York
Journal: JAMA Internal Medicine (2021)

Mission Statement: To promote the art and science of medicine and the betterment of public health by publishing manuscripts of interest and relevance to internists practicing as generalists or as medical subspecialists.
USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study
Authors: Martin C Tammemägi, Mamta Ruparel, Alain Tremblay, Renelle Myers, John Mayo, John Yee, Sukhinder Atkar-Khattra, Ren Yuan, Sonya Cressman, John English, Eric Bedard, Paul MacEachern, Paul Burrowes, Samantha L Quaife, Henry Marshall, Ian Yang, Rayleen Bowman, Linda Passmore, Annette McWilliams, Fraser Brims, Kuan Pin Lim, Lin Mo, Stephen Melsom, Bann Saffar, Mark Teh, Ramon Sheehan, Yijin Kuok, Renee Manser, Louis Irving, Daniel Steinfort, Mark McCusker, Diane Pascoe, Paul Fogarty, Emily Stone, David C L Lam, Ming-Yen Ng, Varut Vardhanabhuti, Christine D Berg, Rayjean J Hung, Samuel M Janes, Kwun Fong, Stephen Lam
Journal: The Lancet Oncology (2021)

Lung cancer is a major health problem. CT lung screening can reduce lung cancer mortality through early diagnosis by at least 20%. Screening high-risk individuals is most effective. Retrospective analyses suggest that identifying individuals for screening by accurate prediction models is more efficient than using categorical age-smoking criteria, such as the US Preventive Services Task Force (USPSTF) criteria. This study prospectively compared the effectiveness of the USPSTF2013 and PLCOm2012 model eligibility criteria.
VITT and Second Doses of Covid-19 Vaccine
Authors: Joanne Lacy, Sue Pavord, Kevin E Brown
Journal: New England Journal of Medicine (2021)

VITT and Second Doses of Covid-19 VaccineTo the Editor: In March 2021, concerns were raised about an increased risk of thrombosis associated with thrombocytopenia among persons who had received their first dose of the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) coronavirus disease 2019 (Covid-19) vaccine.Between 5 and 30 days after vaccination, severe thrombosis developed in these patients, most of whom were previously fit and well.The thrombosis often occurred at unusual or multiple sites, in conjunction with thrombocytopenia, grossly elevated d-dimer levels, reduced fibrinogen levels, 1,2 and the presence of anti-platelet factor 4 (PF4) antibodies.To determine the risk of a second Covid-19 vaccine dose in these patients with vaccine-induced immune thrombotic thrombocytopenia (VITT), the U.K. Health Security Agency (formerly Public Health England) identified the patients who had received a second vaccine dose and contacted the primary care physicians for follow-up.A total of 40 patients were identified as having confirmed (26 patients), probable (2 patients), or possible (12 patients) VITT, as defined in Pavord et al., 3 after receiving their first dose of ChAdOx1 nCoV-19 (Table 1).The patients ranged in age from 21 to 76 years, and 25 were women.Five of the patients had received a second dose of ChAdOx1 nCoV-19, 2 had received mRNA-1273 (Moderna), and 33 had received BNT162b2 (Pfizer-BioNTech).None of the 40 patients had any relapse of symptoms or severe adverse reactions after receiving the second dose of vaccine, regardless of the vaccine received.Although the mechanism of VITT is still not known, 4 the absence of relapse suggests that the phenomenon is not related to the immune response to the spike protein.This conclusion is consistent with that reported by Greinacher et al., 4 who showed that the anti-PF4 antibodies that are detected in patients with VITT do not interact with epitopes on the spike protein and appear to be independent of the spike antibody response.Furthermore, VITT is rarely, if at all, associated with vaccination with nonadenoviral vector vaccines, such as the messen-
Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial
Authors: Monika K Krzyzanowska, Jim A Julian, Chu-Shu Gu, Melanie Powis, Qing Li, Katherine Enright, Doris Howell, Craig C Earle, Sonal Gandhi, Sara Rask, Christine Brezden-Masley, Susan Dent, Leena Hajra, Orit Freeman, Silvana Spadafora, Caroline Hamm, Nadia Califaretti, Maureen Trudeau, Mark N Levine, Eitan Amir, Louise Bordeleau, James A Chiarotto, Christine Elser, Juhi Husain, Nicole Laferriere, Yasmin Rahim, Andrew G Robinson, Ted Vandenberg, Eva Grunfeld
Journal: BMJ (2021)

Abstract Objective To evaluate the effectiveness of remote proactive management of toxicities during chemotherapy for early stage breast cancer. Design Pragmatic, cluster randomised trial. Setting 20 cancer centres in Ontario, Canada, allocated by covariate constrained randomisation to remote management of toxicities or routine care. Participants All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre. 25 patients from each centre completed patient reported outcome questionnaires. Interventions Proactive, standardised, nurse led telephone management of common toxicities at two time points after each chemotherapy cycle. Main outcome measures The primary outcome, cluster level mean number of visits to the emergency department or admissions to hospital per patient during the whole course of chemotherapy treatment, was evaluated with routinely available administrative healthcare data. Secondary patient reported outcomes included toxicity, self-efficacy, and quality of life. Results Baseline characteristics of participants were similar in the intervention (n=944) and control arms (n=1214); 22% were older than 65 years. Penetration (that is, the percentage of patients who received the intervention at each centre) was 50-86%. Mean number of visits to the emergency department or admissions to hospital per patient was 0.91 (standard deviation 0.28) in the intervention arm and 0.94 (0.40) in the control arm (P=0.94); 47% (1014 of 2158 patients) had at least one visit to the emergency department or a hospital admission during chemotherapy. Among 580 participants who completed the patient reported outcome questionnaires, at least one grade 3 toxicity was reported by 48% (134 of 278 patients) in the intervention arm and by 58% (163 of 283) in the control arm. No differences in self-efficacy, anxiety, or depression were found. Compared with baseline, the functional assessment of cancer therapy trial outcome index decreased by 6.1 and 9.0 points in the intervention and control participants, respectively. Conclusions Proactive, telephone based management of toxicities during chemotherapy did not result in fewer visits to the emergency department or hospital admissions. With the rapid rise in remote care because of the covid-19 pandemic, identifying scalable strategies for remote management of patients during cancer treatment is particularly relevant. Trial registration ClinicalTrials.gov NCT02485678 .
66P Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
Authors: X. Wang, J. Ma, J. Zhang, Y. Yang, D. Zheng, H. Liang, L. Zhang, Y. Xin, X. Ling, C. Fang, H. Jiang, W. Zheng
Journal: Annals of Oncology (2021)
74P Predicting the risk of immunotherapy-induced versus other-cause pneumonitis in stage IV non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors
Authors: F. Tohidinezhad, L. Hendriks, A-M.C. Dingemans, J.G. Aerts, G. Bootsma, J.F. Vansteenkiste, S. Hashemi, E.F. Smit, H. Gietema, H.J. Aerts, A. Dekker, A. Traverso, D. De Ruysscher
Journal: Annals of Oncology (2021)
Effect of high <i>versus</i> low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial
Authors: Manuel Taboada, Nuria Rodríguez, Pablo Manuel Varela, María Teresa Rodríguez, Romina Abelleira, Amara González, Ana Casal, José Antonio Díaz Peromingo, Adriana Lama, María Jesús Domínguez, Carlos Rábade, Emilio Manuel Páez, Vanessa Riveiro, Hadrián Pernas, María del Carmen Beceiro, Valentín Caruezo, Alberto Naveira, Agustín Cariñena, Teresa Cabaleiro, Ana Estany-Gestal, Irene Zarra, Antonio Pose, Luis Valdés, Julián Álvarez-Escudero
Journal: European Respiratory Journal (2021)

Low-dose dexamethasone demonstrated clinical improvement in patients with coronavirus disease 2019 (COVID-19) needing oxygen therapy; however, evidence on the efficacy of high-dose dexamethasone is limited.We performed a randomised, open-label, controlled trial involving hospitalised patients with confirmed COVID-19 pneumonia needing oxygen therapy. Patients were randomly assigned in a 1:1 ratio to receive low-dose dexamethasone (6 mg once daily for 10 days) or high-dose dexamethasone (20 mg once daily for 5 days, followed by 10 mg once daily for an additional 5 days). The primary outcome was clinical worsening within 11 days since randomisation. Secondary outcomes included 28-day mortality, time to recovery and clinical status at day 5, 11, 14 and 28 on an ordinal scale ranging from 1 (discharged) to 7 (death).A total of 200 patients (mean±sd age 64±14 years; 62% male) were enrolled. 32 (31.4%) out of 102 patients enrolled in the low-dose group and 16 (16.3%) out of 98 in the high-dose group showed clinical worsening within 11 days since randomisation (rate ratio 0.427, 95% CI 0.216-0.842; p=0.014). The 28-day mortality was 5.9% in the low-dose group and 6.1% in the high-dose group (p=0.844). There was no significant difference in time to recovery, and in the seven-point ordinal scale at days 5, 11, 14 and 28.Among hospitalised COVID-19 patients needing oxygen therapy, high dose of dexamethasone reduced clinical worsening within 11 days after randomisation, compared with low dose.
120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
Authors: J.C-H. Yang, A. Luft, E. De La Mora Jiménez, J.S. Lee, P. Koralewski, N. Karadurmus, S. Sugawara, L. Livi, N.S. Basappa, X. Quantin, J. Dudnik, D. Moran Ortiz, T. Mekhail, C.E. Okpara, Z. Zimmer, A. Samkari, N. Bhagwati, T. Csőszi
Journal: Annals of Oncology (2021)